Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | GRK2 | P25098 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279958 | 0.85 | CYP2C19 (0.72) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL14139926 | 0.85 | CD274 (0.71) | EPHX2POLBCD274HPGDALDH1A1 | |
| SCHEMBL9312796 | 0.84 | CYP2C19 (0.70) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL9312802 | 0.84 | CYP2C19 (0.71) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL10264071 | 0.83 | CYP2C19 (0.69) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL29584690 | 0.82 | CYP2C19 (0.69) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL2720343 | 0.82 | CYP2C19 (0.69) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL4572822 | 0.82 | CYP2C19 (0.69) | EPHX2CYP2C19CYP2C9POLBCYP1A2 | |
| SCHEMBL15822962 | 0.82 | CYP2C19 (1.00) | CYP2C19CYP2C9POLBCYP1A2CYP2D6 | |
| SCHEMBL30098940 | 0.82 | CYP2C19 (1.00) | CYP2C19CYP2C9POLBCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | CASP3, BCL3, ME3 | EPHX2 3147/4885CYP2C19 2108/4885CYP2C9 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.